|Author||Gurwith M, Condit RC, Excler JL, Robertson JS, Kim D, Fast PE, Drew S, Wood D, Klug B, Whelan M, Mallett Moore T, Khuri-Bulos N, Smith ER, Chen RT, Kochhar S|
|Title||Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.|
|Month / Year||01/2021|
|Vol (No)||38 (49)|
|Page||7702 ~ 7|
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed live-attenuated viral vaccines.
|Keyword||COVID-19 Vaccines/adverse effects/pharmacology; Drug Evaluation, Preclinical/methods/*standards; Humans; Risk Assessment; Societies, Scientific; Vaccines, Attenuated/*adverse effects/pharmacology; Viral Vaccines/*adverse effects/pharmacology|